Informizely customer feedback surveys

[Skip to content]

Southern Health 70 years of the NHS; 1948 - 2018
Search our Site

Elad Study - Evaluating the effects of the novel GLP-1 analogue, Liraglutide, in patients with Alzheimer’s disease

Principal Investigator:  Dr Brady McFarlane 
Study Coordinator:        Annette Stevens

Alzheimer’s disease (AD) is thought to affect 10% of individuals over 65 years, rising to over 40% in those aged over 85 years. There is currently no treatment that can prevent the disease and the only available treatments help with symptom control only.

Given the urgent need for an effective treatment, we are carrying out a study to evaluate the effect of a drug that is already used for the treatment of diabetes, in AD.

Diabetes has been identified as a risk factor for AD and it has been shown that regulation of insulin is abnormal in AD brains. This study has two groups, but neither the participant nor the investigator will know which group participants are in. One group will be given the study drug (liraglutide) and the other group will be given a placebo (dummy drug, containing exactly the same solution as in the study drug, but without the liraglutide). The drug is injected every day under the skin of the abdomen, thigh or upper arm. Participants have a 50% chance of receiving the study drug.

Who could be suitable?

We are looking for volunteers with a diagnosis of Alzheimers disease who are over the age of 50 years old, with a MMSE score of between 15-30.

If you are interested in finding out more or if you would like to find out whether you would be suitable for this study please contact the MARC team on 02380 475206.


Find out more

To find out more please email